Brainsway Ltd
Research Brainsway Ltd (BWAY) on Bullrun: market cap USD 579.07M, P/E 60.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBWAY
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 579.07M
- P/E60.8
- Financial periodQ1 2026
- RevenueUSD 15.53M
- Net incomeUSD 2.29M
- Free cash flowUSD 402.00K
- Gross margin75.2%
Valuation Snapshot
latest market cap is USD 579.07M; P/E is 60.8.
Peer valuation comparison
Latest P/E is 60.76x versus a Healthcare sector median of 24.46x (148.4% above).
Latest P/E is 60.76x versus a Israel median of 24.26x (150.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 52.23M | USD 7.63M | USD 15.01M | 75.4% | 0.18 | USD 67.70M | USD 6.82M | USD 73.22M |
| FY2024 | USD 41.02M | USD 2.92M | USD 6.50M | 74.6% | 0.06 | USD 69.35M | USD 5.62M | USD 62.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 579.07M | 60.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 372.42M | 45.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 177.60M | 39.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 107.70M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.01M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 126.71M | n/a | n/a | n/a |
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Brainsway Ltd's market cap?
Brainsway Ltd's market capitalization is USD 579.07M.
What is Brainsway Ltd's P/E ratio?
Brainsway Ltd's price-to-earnings (P/E) ratio is 60.8.
What does Brainsway Ltd do?
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.